Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) — Tangible Net Worth Ratio
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has a Tangible Net Worth Ratio of 93.6% as of September 2025. This metric is calculated by deducting intangible assets (CN¥174.63 Million) from net assets (CN¥2.73 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See how liquid is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Tangible Net Worth Ratio (2009–2024)
This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 16 annual periods from 2009 to 2024. As of September 2025, the ratio stands at 93.6%, reflecting net assets of CN¥2.73 Billion with intangible assets of CN¥174.63 Million CNY. See Zhejiang Wolwo Bio-Pharmaceutical Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024, covering 16 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see market value of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 92.6% | CN¥2.46 Billion | CN¥181.53 Million | CN¥2.71 Billion | ▲ +0.8 pp |
| 2023 | 91.8% | CN¥2.30 Billion | CN¥188.42 Million | CN¥2.56 Billion | ▲ +1.2 pp |
| 2022 | 90.7% | CN¥2.03 Billion | CN¥189.50 Million | CN¥2.20 Billion | ▲ +0.5 pp |
| 2021 | 90.2% | CN¥1.80 Billion | CN¥176.35 Million | CN¥1.93 Billion | ▲ +1.3 pp |
| 2020 | 88.8% | CN¥1.53 Billion | CN¥170.42 Million | CN¥1.60 Billion | ▲ +0.8 pp |
| 2019 | 88.1% | CN¥1.35 Billion | CN¥160.94 Million | CN¥1.43 Billion | ▲ +0.5 pp |
| 2018 | 87.6% | CN¥995.42 Million | CN¥123.35 Million | CN¥1.06 Billion | ▼ -5.8 pp |
| 2017 | 93.4% | CN¥801.26 Million | CN¥53.14 Million | CN¥848.31 Million | ▼ -1.0 pp |
| 2016 | 94.4% | CN¥655.58 Million | CN¥36.76 Million | CN¥696.89 Million | ▼ -0.8 pp |
| 2015 | 95.2% | CN¥582.91 Million | CN¥27.78 Million | CN¥611.49 Million | ▼ -0.5 pp |
| 2014 | 95.8% | CN¥513.55 Million | CN¥21.79 Million | CN¥531.31 Million | ▲ +3.5 pp |
| 2013 | 92.3% | CN¥251.92 Million | CN¥19.40 Million | CN¥263.95 Million | ▲ +1.2 pp |
| 2012 | 91.1% | CN¥181.38 Million | CN¥16.20 Million | CN¥191.11 Million | ▲ +2.5 pp |
| 2011 | 88.6% | CN¥127.61 Million | CN¥14.58 Million | CN¥147.19 Million | ▲ +3.1 pp |
| 2010 | 85.4% | CN¥90.44 Million | CN¥13.17 Million | CN¥110.52 Million | ▼ -3.4 pp |
| 2009 | 88.8% | CN¥111.89 Million | CN¥12.51 Million | CN¥121.38 Million | — |